Investor Alert

New York Markets Open in:

Teva Pharmaceutical Industries Ltd. ADR



Before the Bell

 --Real time quotes

Feb 9, 2023, 7:36 a.m.





+0.11 +1.11%


Volume 43,377

Real time quotes


Previous close

$ 9.92

$ 9.92


-0.97 -8.91%

Day low

Day high




52 week low

52 week high




Annual Financials for Teva Pharmaceutical Industries Ltd. ADR

Fiscal year is January-December. All values ILS millions. 20172018201920202021 5-year trend
Sales/Revenue 80.52B65.69B60.12B57.29B51.19B
Cost of Goods Sold (COGS) incl. D&A 42.34B35.86B33.32B30.72B27.08B
COGS excluding D&A 34.87B29.24B27.18B25.37B22.78B
Depreciation & Amortization Expense 7.47B6.62B6.14B5.35B4.3B
Depreciation 2.27B2.43B2.17B1.85B1.71B
Amortization of Intangibles 5.19B4.19B3.97B3.51B2.59B
Gross Income 38.18B29.83B26.8B26.57B24.11B
20172018201920202021 5-year trend
SG&A Expense 23.83B19.51B17.16B16.05B14.2B
Research & Development 6.4B4.36B3.6B3.43B3.12B
Other SG&A 17.43B15.15B13.56B12.62B11.08B
Other Operating Expense -----
Unusual Expense 81.2B16.96B11.1B23.29B4.35B
EBIT after Unusual Expense (81.2B)(16.96B)(1.46B)(12.78B)5.56B
Non Operating Income/Expense 3.26B553.67M213.78M137.56M(187.35M)
Non-Operating Interest Income 302.15M140.22M146.08M82.54M-
Equity in Affiliates (Pretax) -----
Interest Expense 2.83B3.38B3.41B2.6B3.25B
Gross Interest Expense 2.83B3.38B3.41B2.6B3.25B
Interest Capitalized -----
Pretax Income (66.11B)(9.33B)(4.51B)(15.15B)2.13B
Income Tax (6.95B)(701.08M)(990.52M)(577.76M)681.56M
Income Tax - Current Domestic 1.34B2.52B3.15B625.9M872.13M
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic (8.29B)(3.22B)(4.14B)(1.2B)(190.58M)
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates (10.79M)(255.26M)(46.32M)474.59M29.07M
Other After Tax Income (Expense) -----
Consolidated Net Income (59.17B)(8.89B)(3.56B)(14.1B)1.47B
Minority Interest Expense (661.84M)(1.16B)(3.56M)(378.29M)125.97M
Net Income (58.5B)(7.73B)(3.56B)(13.72B)1.35B
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (58.5B)(7.73B)(3.56B)(13.72B)1.35B
Preferred Dividends 935.21M895.22M---
Net Income Available to Common (59.44B)(8.63B)(3.56B)(13.72B)1.35B
EPS (Basic) (58.50)(8.45)(3.26)(12.53)1.22
Basic Shares Outstanding 1.02B1.02B1.09B1.1B1.1B
EPS (Diluted) (58.50)(8.45)(3.26)(12.53)1.22
Diluted Shares Outstanding 1.02B1.02B1.09B1.1B1.11B
EBITDA 21.82B16.94B15.78B15.87B14.21B
Link to MarketWatch's Slice.